Myriad
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.
Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch
Premium
At ASCO, the company detailed its efforts to make the 93-SNP riskScore, which it plans to offer as a standalone DTC test next year, relevant for women of all ancestries.
In Brief This Week: Oncocyte, Qiagen, Myriad Genetics, Iaso Biotherapeutics
News items for the week of May 31, 2021.Â
Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M
The sale, part of Myriad's planned strategic refocusing of its business, will allow Castle to bolster its pipeline of tests for dermatologic cancers.
In Brief This Week: Mirati Therapeutics, Gilead, Natera, Actinium Pharmaceuticals, Myriad Genetics
News items for the week of March 22, 2021.Â